HomepageNVZMY • OTCMKTS
add
Novozymes
$Â 59,38
Na sluitingstijd:(0,51%)+0,30
$Â 59,68
Gesloten: 22 nov, 16:27:15 GMT-5 · USD · OTCMKTS · Disclaimer
Vorige slotkoers
$Â 57,46
Dag-range
$Â 59,22 - $Â 59,80
Jaar-range
$Â 49,99 - $Â 72,50
Beurswaarde
176,44Â mld. DKK
Gem. volume
12,10K
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(EUR) | jun 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 915,85Â mln. | 61,70% |
Bedrijfskosten | 271,75Â mln. | 52,62% |
Netto inkomsten | 31,95Â mln. | -60,72% |
Netto winstmarge | 3,49 | -75,70% |
Winst per aandeel | — | — |
EBITDA | 150,94Â mln. | -16,50% |
Effectief belastingtarief | 29,00% | — |
Balans
Totale activa
Totale passiva
(EUR) | jun 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 260,80Â mln. | 85,35% |
Totale activa | 15,25Â mld. | 302,43% |
Totale passiva | 4,25Â mld. | 119,23% |
Totaal aandelenvermogen | 11,00 mld. | — |
Uitstaande aandelen | 277,90 mln. | — |
Koers-boekwaardeverhouding | 1,45 | — |
Rendement op activa | 1,83% | — |
Rendement op kapitaal | 2,15% | — |
Kasstroom
Nettomutatie in liquide middelen
(EUR) | jun 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | 31,95Â mln. | -60,72% |
Operationele kasstroom | 264,05Â mln. | 74,01% |
Kasstroom uit beleggingen | -27,45Â mln. | 70,98% |
Kasstroom uit financiering | -186,70Â mln. | -205,10% |
Nettomutatie in liquide middelen | 55,55Â mln. | 902,56% |
Vrije kasstroom | -17,57Â mln. | 68,87% |
Over
Novozymes A/S was a global biotechnology company headquartered in Bagsværd, outside of Copenhagen, Denmark. The company's focus was the research, development and production of industrial enzymes, microorganisms, and biopharmaceutical ingredients. The company merged with Chr. Hansen to form Novonesis in January 2024.
Prior to the merger, the company had operations around the world, including in China, India, Brazil, Argentina, United Kingdom, the United States, and Canada. Class B shares of its stock were listed on the NASDAQ OMX Nordic exchange.
On 12 December 2023, it was announced that Novozymes and Danish bioscience company Chr. Hansen had obtained regulatory approval for a merger, and on the following day, the name of the combined company was revealed as Novonesis. Wikipedia
CEO
Opgericht
2000
Website
Werknemers
10.452